| Not Yet Recruiting | Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC NCT07405190 | Massachusetts General Hospital | Phase 2 |
| Not Yet Recruiting | Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib NCT07486648 | Shanxi Province Cancer Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | SERS-Based Serum Molecular Spectral Screening for Lung Cancer Type NCT06775002 | Fuzhou General Hospital | — |
| Not Yet Recruiting | Immune Response to Immunotherapy in Lung Cancer: Study of Sputum and Blood Samples NCT07163507 | University Hospital, Tours | N/A |
| Not Yet Recruiting | Effectiveness of a Multimodal Outpatient Supervised Physical Activity Program to Improve Tolerance and Efficac NCT07502963 | University of Vic - Central University of Catalonia | N/A |
| Recruiting | Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery NCT07500376 | Ondokuz Mayıs University | — |
| Recruiting | Engagement of Veterans With Lung Cancer NCT07219251 | Palo Alto Veterans Institute for Research | N/A |
| Not Yet Recruiting | SL-28 for Advanced Solid Tumours NCT07341737 | Second Life Therapeutics | Phase 1 / Phase 2 |
| Not Yet Recruiting | Association of Different Tidal Volumes and Postoperative Pulmonary Complications NCT07372378 | First Affiliated Hospital of Zhejiang University | — |
| Recruiting | A Phase II Study of SKB571 in Patients With Lung Cancer NCT07230405 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient- NCT06405230 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Not Yet Recruiting | The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer NCT07216209 | University of Arizona | N/A |
| Recruiting | IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation NCT07198841 | Guangdong Association of Clinical Trials | Phase 2 |
| Not Yet Recruiting | Analysis of Circulating Tumor Markers in Blood - ALCINA 5 NCT07060950 | Institut du Cancer de Montpellier - Val d'Aurelle | N/A |
| Recruiting | Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors NCT07145255 | MBrace Therapeutics | Phase 1 / Phase 2 |
| Enrolling By Invitation | Evaluating the Feasibility and Preliminary Effects of BE+ NCT07214441 | University of South Carolina | N/A |
| Recruiting | Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer NCT06963307 | JaxBio Ltd | — |
| Recruiting | Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer NCT07166003 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | — |
| Active Not Recruiting | Exploration of Risk Factors for Postoperative Cerebral Infarction in Lung Cancer Patients: a Retrospective Sin NCT06942845 | Xinghua Cheng | — |
| Recruiting | Sleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques NCT06687408 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Recruiting | Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3) NCT06926790 | The First Affiliated Hospital of Guangzhou Medical University | Phase 2 |
| Recruiting | A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC NCT06769295 | Sichuan University | Phase 2 |
| Not Yet Recruiting | Comprehensive Demographics and Clinical Profile of NSCLC Patients NCT06725537 | D'Or Institute for Research and Education | — |
| Recruiting | Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer NCT06889467 | Barzilai Medical Center | — |
| Not Yet Recruiting | Reinforced and Non-Reinforced Staple Lines in Fissureless Lobectomy NCT06602661 | Surrey Thoracic Surgery Group | Phase 1 |
| Recruiting | Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients NCT06659458 | Our Lady of the Lake Hospital | — |
| Not Yet Recruiting | The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detecti NCT06739421 | China-Japan Friendship Hospital | N/A |
| Not Yet Recruiting | A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NCT06690671 | Shanghai Chest Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | Transbroncheal Novel PDT Peripheral Lung Tumor Ablation With 5-ALA NCT06679712 | Taoyuan General Hospital | N/A |
| Recruiting | Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions NCT06648317 | Peking University Cancer Hospital & Institute | — |
| Recruiting | Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer NCT06659042 | Shanghai Chest Hospital | Phase 2 |
| Not Yet Recruiting | Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC NCT06690541 | Peking University Cancer Hospital & Institute | — |
| Completed | A Clinical Evaluation of AI Solutions Developed in the CHAIMELEON Project for Cancer: Prostate, Lung, Breast, NCT06950996 | Instituto de Investigacion Sanitaria La Fe | — |
| Withdrawn | Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer NCT06555263 | Sutro Biopharma, Inc. | Phase 2 |
| Recruiting | TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer NCT06538012 | Essen Biotech | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Parti NCT06472076 | GlaxoSmithKline | Phase 3 |
| Recruiting | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs NCT06228326 | Krystal Biotech, Inc. | Phase 1 / Phase 2 |
| Recruiting | Standard Care With or Without Early Palliative Care Provided by Palliative Care Specialist in Advanced Non-sma NCT06786468 | Mahidol University | N/A |
| Completed | RaFIST: A Radiomics-Based Tool for Intratumoral Fibrosis Stratification in Non-Small Cell Lung Cancer NCT06908005 | Jinling Hospital, China | — |
| Recruiting | TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO NCT05628376 | University College, London | — |
| Completed | Integrating Machine Learning for Prognostic Prediction in Stage I NSCLC by CT Images and Pathological Factors NCT06737367 | Jinling Hospital, China | — |
| Active Not Recruiting | Evaluation of Efficacy of Minimally Invasive Local Therapy for Lung Tumors and Its Impact on Breathing Functio NCT07272356 | Aurimas Macionis | N/A |
| Active Not Recruiting | Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC) NCT05784142 | Jiangsu Cancer Institute & Hospital | Phase 2 |
| Active Not Recruiting | A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metas NCT05565378 | GlaxoSmithKline | Phase 2 |
| Completed | IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCH NCT05077709 | IO Biotech | Phase 2 |
| Unknown | Neoadjuvant Immunotherapy in Advanced NSCLC NCT05137912 | Power Life Sciences Inc. | — |
| Recruiting | Shared Decision Making on Radiation Dose for Lung Malignancies NCT04940936 | Vejle Hospital | N/A |
| Recruiting | Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-po NCT05598528 | Second Xiangya Hospital of Central South University | — |
| Terminated | Molecular Disease Characterization Initiative (MDCI) NCT04772053 | GlaxoSmithKline | Phase 2 |
| Active Not Recruiting | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors NCT04660929 | Carisma Therapeutics Inc | Phase 1 |
| Active Not Recruiting | Quality of Life as a Predictor of OS and PFS in Patients With Lung Cancer NCT06900283 | Instituto Nacional de Cancerologia, Columbia | — |
| Active Not Recruiting | Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Pa NCT04655976 | GlaxoSmithKline | Phase 3 |
| Unknown | Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment NCT04706949 | Fudan University | Phase 2 |
| Unknown | Baduanjin Exercise on Meridian Energy, Lung Function and Heart Rate Variability in Patients Undergoing Lung Op NCT04669730 | Tzu Chi University | N/A |
| Active Not Recruiting | NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer NCT04986670 | Tufts University | N/A |
| Terminated | Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants Wi NCT04581824 | GlaxoSmithKline | Phase 2 |
| Active Not Recruiting | Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenan NCT04475939 | GlaxoSmithKline | Phase 3 |
| Unknown | Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer NCT04592666 | Fudan University | Phase 2 |
| Unknown | Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC NCT04541251 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Completed | Appropriate Dosing to Optimise Personalised Cancer Treatments NCT04154163 | University of Dundee | — |
| Unknown | Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors. NCT04595734 | Western Sydney Local Health District | — |
| Terminated | Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivo NCT04069936 | WindMIL Therapeutics | Phase 2 |
| Completed | Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil NCT03836469 | Latin American Cooperative Oncology Group | — |
| Completed | Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer NCT03847519 | Advaxis, Inc. | Phase 1 / Phase 2 |
| Unknown | Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC NCT02824952 | Shaare Zedek Medical Center | Phase 2 |
| Unknown | Volatil Organic Compounds in Exhaled Air and Sweat After Thoracic Surgery for Carcinological Resection NCT03803137 | Hopital Foch | N/A |
| Terminated | Volatile Organic Compounds in Exhaled Air and Sweat of Patients Treated by Immunotherapy for Lung Cancer: Rese NCT03988192 | Hopital Foch | N/A |
| Unknown | Effects of VNS on RT-induced Inflammation and Prognosis of Patients With NSCLC NCT03553485 | Vrije Universiteit Brussel | N/A |
| Terminated | Cardiac MRI Biomarker Testing (GCC 1618) NCT02688166 | University of Maryland, Baltimore | — |
| Terminated | Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors NCT03272971 | Broncus Medical Inc | N/A |
| Withdrawn | Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell L NCT01938456 | GlaxoSmithKline | Phase 1 |
| Completed | NSCLC Burden of Illness Study NCT01772225 | GlaxoSmithKline | — |
| Completed | A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of NCT01853878 | GlaxoSmithKline | Phase 2 |
| Terminated | Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer NCT01471197 | Bristol-Myers Squibb | Phase 2 |
| Completed | An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer NCT01362296 | GlaxoSmithKline | Phase 2 |
| Unknown | Immunotherapy With Racotumomab in Advanced Lung Cancer NCT01460472 | Recombio SL | Phase 3 |
| Terminated | Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by S NCT01159964 | GlaxoSmithKline | Phase 1 |
| Completed | Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer NCT00866528 | GlaxoSmithKline | Phase 1 |
| Completed | Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer NCT00871403 | GlaxoSmithKline | Phase 2 |
| Terminated | Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma NCT00685750 | GlaxoSmithKline | N/A |
| Completed | A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for A NCT00678977 | GlaxoSmithKline | Phase 1 |
| Completed | A Study of Lymph Node Metastatic Pattern Based Incorporating Tumor Location, GGO Components and Size for Non-s NCT06161935 | Fudan University | — |
| Terminated | Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 | GlaxoSmithKline | Phase 2 |
| Completed | A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors NCT00619424 | GlaxoSmithKline | Phase 1 |
| Terminated | GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung NCT00480025 | GlaxoSmithKline | Phase 3 |
| Completed | A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an In NCT00528281 | GlaxoSmithKline | Phase 1 |
| Terminated | Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell L NCT00455572 | GlaxoSmithKline | Phase 1 |
| Completed | Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lun NCT00390806 | GlaxoSmithKline | Phase 3 |
| Completed | Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer NCT00367679 | GlaxoSmithKline | Phase 2 |
| Terminated | A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer NCT00073008 | GlaxoSmithKline | Phase 2 |
| Completed | Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cance NCT00065182 | GlaxoSmithKline | Phase 2 |
| Completed | Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Remov NCT00290355 | GlaxoSmithKline | Phase 2 |
| Completed | Application of Machine Learning Algorithms to Identify Optimal Candidates for Primary Tumor Resection in Patie NCT06621147 | Hongquan Xing | — |
| Available | Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors NCT06872489 | Second Life Therapeutics | — |